423 related articles for article (PubMed ID: 32034799)
1. Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.
Sanyal A; DeAndrade MP; Novis HS; Lin S; Chang J; Lengacher N; Tomlinson JJ; Tansey MG; LaVoie MJ
Mov Disord; 2020 May; 35(5):760-773. PubMed ID: 32034799
[TBL] [Abstract][Full Text] [Related]
2. The Effect of p.G2019S Mutation in the
Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
[TBL] [Abstract][Full Text] [Related]
3. LRRK2 Kinase Inhibition Rescues Deficits in Lysosome Function Due to Heterozygous
Sanyal A; Novis HS; Gasser E; Lin S; LaVoie MJ
Front Neurosci; 2020; 14():442. PubMed ID: 32499675
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.
Volta M
Neurotherapeutics; 2023 Jan; 20(1):127-139. PubMed ID: 36085537
[TBL] [Abstract][Full Text] [Related]
5. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
Lee CY; Menozzi E; Chau KY; Schapira AHV
J Neurochem; 2021 Dec; 159(5):826-839. PubMed ID: 34618942
[TBL] [Abstract][Full Text] [Related]
6. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
7. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease.
Duran R; Mencacci NE; Angeli AV; Shoai M; Deas E; Houlden H; Mehta A; Hughes D; Cox TM; Deegan P; Schapira AH; Lees AJ; Limousin P; Jarman PR; Bhatia KP; Wood NW; Hardy J; Foltynie T
Mov Disord; 2013 Feb; 28(2):232-236. PubMed ID: 23225227
[TBL] [Abstract][Full Text] [Related]
8. Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.
Surface M; Balwani M; Waters C; Haimovich A; Gan-Or Z; Marder KS; Hsieh T; Song L; Padmanabhan S; Hsieh F; Merchant KM; Alcalay RN
Mov Disord; 2022 Feb; 37(2):416-421. PubMed ID: 34741486
[TBL] [Abstract][Full Text] [Related]
9. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.
García-Sanz P; Orgaz L; Bueno-Gil G; Espadas I; Rodríguez-Traver E; Kulisevsky J; Gutierrez A; Dávila JC; González-Polo RA; Fuentes JM; Mir P; Vicario C; Moratalla R
Mov Disord; 2017 Oct; 32(10):1409-1422. PubMed ID: 28779532
[TBL] [Abstract][Full Text] [Related]
10. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
11. PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects,
Zhao X; Lin Y; Liou B; Fu W; Jian J; Fannie V; Zhang W; Setchell KDR; Grabowski GA; Sun Y; Liu CJ
Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2210442120. PubMed ID: 36574647
[TBL] [Abstract][Full Text] [Related]
12. GBA1-and LRRK2-directed Treatments: The Way Forward.
Maayan Eshed G; Alcalay RN
Parkinsonism Relat Disord; 2024 May; 122():106039. PubMed ID: 38438297
[TBL] [Abstract][Full Text] [Related]
13. Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach.
Menozzi E; Schapira AHV; Blandini F; Avenali M
Curr Neurol Neurosci Rep; 2023 Apr; 23(4):121-130. PubMed ID: 36881256
[TBL] [Abstract][Full Text] [Related]
14. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
[TBL] [Abstract][Full Text] [Related]
15. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
[TBL] [Abstract][Full Text] [Related]
16. Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line.
Ruz C; Alcantud JL; Vives F; Arrebola F; Hardy J; Lewis PA; Manzoni C; Duran R
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805938
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.
Parnetti L; Paciotti S; Eusebi P; Dardis A; Zampieri S; Chiasserini D; Tasegian A; Tambasco N; Bembi B; Calabresi P; Beccari T
Mov Disord; 2017 Oct; 32(10):1423-1431. PubMed ID: 28843015
[TBL] [Abstract][Full Text] [Related]
18. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
[TBL] [Abstract][Full Text] [Related]
19. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
